Indication: Hospitalized patients with Severe COVID-19
Title: Phase 2 Randomized Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor in Patients with Severe COVID-19
Drug: Selinexor

This study has been discontinued as of August 2020

Please visit for more information about this study


Drug: Selinexor

Early StageMid StageLate StageCommercial
Early Stage
Mid Stage
Late Stage